Editorial process

What our articles are

The articles in our research-peptide guides explain what a compound is, what biological pathways researchers study it in, and how it is supplied and verified. They are research-framed: written for laboratory contexts and people deciding whether a research peptide is relevant to a study. They are not medical advice, dosing guidance, or instructions for use in humans or animals.

How they are drafted

• First drafts are produced by our editorial team with assistance from AI tools (we use Claude, by Anthropic). AI is a productivity step, not a source of truth.
• Every draft is then read and edited by a named human contributor before it is published. Articles in the Drafts queue do not appear on the public hub.
• We deliberately avoid clinical claims, dosing language, and prescriptive instructions. Where a topic is sensitive — for example UK legality — we mark it explicitly as YMYL and require an extra review step before publishing.

How sources are chosen

• Mechanism, structure and pathway claims are anchored to peer-reviewed literature surfaced via PubMed.
• Statements about UK law (the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, advertising rules under the CAP Code) are anchored to legislation.gov.uk and the relevant regulator’s published guidance.
• Citations appear at the bottom of every article that makes a factual claim. We don’t cite our own marketing copy or unverifiable blog posts as sources.

Bylines and reviewer credit

Every article carries a named author byline. Articles on YMYL topics (Your Money or Your Life — legality, scientific claims with health implications) carry an additional reviewer credit with the reviewer’s role and credentials. Where we do not yet have a qualified named reviewer for a YMYL topic, we say so plainly rather than hide the gap behind a generic byline.

We do not invent credentials. If you read a name with a regulator number after it, that number is real and you can verify it with the regulator.

How articles are kept current

• Every article has a visible “last reviewed” date that also drives the dateModified field in our structured data.
• When UK law or a referenced source changes materially, we re-review and re-date the affected articles.
• If you spot an error or a stale source, please write to us at hello@my-peptides.co.uk.

Commercial relationship

MY PEPTIDES is a research-grade peptide supplier. The articles describe compounds we sell. We are not impartial about the existence of these compounds — that’s the business we’re in. We are impartial about the science: a study or a statute says what it says regardless of whether we sell the related SKU.